Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 17;134(18):e184846.
doi: 10.1172/JCI184846.

Checkpoint therapy in cancer treatment: progress, challenges, and future directions

Mesude Bicak  1   2 , Cansu Cimen Bozkus  1   2 , Nina Bhardwaj  1   2   3
Affiliations

Checkpoint therapy in cancer treatment: progress, challenges, and future directions

Mesude Bicak et al. J Clin Invest. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: The authors have declared that no conflict of interest exists.

Figures

Figure 1
Figure 1. Milestones in cancer research.
(A) Historical milestones in cancer research include discoveries, Nobel Prizes, and FDA approvals. (B) Immune checkpoint blockade with anti–CTLA-4 and anti-PD1 antibodies acts via T cells. Upon binding to their ligands, checkpoint receptors expressed on T cells, including PD-1 and CTLA-4, mediate suppression of T cell–mediated tumor killing. Blocking checkpoint receptor signaling using monoclonal antibodies can restore T cell function, leading to successful tumor killing. PFN, perforin; GzmB, granzyme B.
See this image and copyright information in PMC

References

    1. Hui E, et al. T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition. Science. 2017;355(6332):1428–1433. doi: 10.1126/science.aaf1292. - DOI - PMC - PubMed
    1. Marcus L, et al. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res. 2019;25(13):3753–3758. doi: 10.1158/1078-0432.CCR-18-4070. - DOI - PubMed
    1. Ayers M, et al. IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):2930–2940. doi: 10.1172/JCI91190. - DOI - PMC - PubMed
    1. Deng L, et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest. 2014;124(2):687–695. doi: 10.1172/JCI67313. - DOI - PMC - PubMed
    1. Sordo-Bahamonde C, et al. Chemo-immunotherapy: a new trend in cancer treatment. Cancers (Basel) 2023;15(11):2912. doi: 10.3390/cancers15112912. - DOI - PMC - PubMed

Substances